F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 2 disclosed transactions, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. concentrates its licensing activity in Metabolic, Other. F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. pays a 1.01x premium over market median. Their most common deal structure is Co Development, with an average disclosed value of $4.2B. Most recent activity: 2025.
Pipeline coverage & gaps
F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| Co DevelopmentPrimary | 2 | $1.2B | $4.2B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | Petrelintide | Zealand Pharma | obesity | unknown | $1.6B | $5.3B |
| 2024 | targeted protein modulation programs | Nurix | — | unknown | $700M | $3.0B |
How this is computed
For each F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 1.010, clamped to [0.7, 1.5].